Login
Breaking News
FactSet Research   Lennar   FedEx Corp   Scholastic   Darden Restaurants   Cracker Barrel   Hain Celestial   Dave & Buster’s   Designer Brands  

Cyteir therapeutics inc.

Biotechnology:-Biological-Products-(No-Diagnostic-Substances)

CYT



,
Investor Relation

Executive/
Director

Executive/Director

Links

10K
10Q
Prospectus

Price

  • Last Close
  • $ 3.02
    $ -0.07 -2.27 %
    Mar 15, 2024
  • 52-Week High/Low
  • $3.15 - $2.75
  • YTD
  • 0%

  • Trading Volume
  • 1,006,884
  • Market Cap Full
  • $ 108.7M
  • Shares Outstanding
  • 36M
    Aug 4, 2023

Returns +
Q

2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Q1 - - - - - - -66.8% 10.3% -0.7% -
Q2 - - - - - 26.6% -20.7% 42.9% - -
Q3 - - - - - -18% -35.8% 9.2% - -
Q4 - - - - - -35.2% -14.1% 7% - -

Returns +
M
J F M A M J J A S O N D
2025 - - - - - - - - - - - -
2024 2% 0.3% -2.9% - - - - - - - - -

Returns +
A
    2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
    0%0%0%0%0%0%0%-85%84%-1%0%

Earnings

2021 2022 2023
Q1 -3.4 -0.4 -0.35
Q2 -4.83 -0.34 -0.24
Q3 -0.33 -0.31 -0.10
Q4 6.4 -0.26 -
A -2.2 -1.3 -0.69

Annual Returns

52 Week
High/Low

Annual
Earnings

Chart

Trading Volume

Outstanding Shares
(In Millions) +

Jan 16, 2024
2021 2022 2023
Mar - 35.4 35.6
Jun - 35.4 35.5
Sep 35.4 35.4 36
Dec 35.4 35.4 -

Financial Statements
+

Annual
Download

SEC Filings

Date Form Type SEC Filings
Mar 29, 2024 15-12G Financial Statements
Mar 25, 2024 4 Financial Statements
Mar 20, 2024 8-K Financial Statements
Mar 18, 2024 25 Financial Statements
Mar 18, 2024 POS AM Financial Statements
Mar 13, 2024 EFFECT Financial Statements
Feb 14, 2024 SC 13G/A Financial Statements
Feb 7, 2024 SC 13G/A Financial Statements
Jan 19, 2024 SC 13G/A Financial Statements
Dec 27, 2023 8-K Financial Statements

Financial Ratios

20222021202020192018
Asset Management
Inventory / Stock Turnover - - - - -
Total Asset Turnover - - - - -
Fixed Asset Turnover - - - - -
Leverage
Debt Ratio - - - - -
Debt – Equity Ratio - - - - -
Interest Coverage 24 - - - -
Equity multiplier - - - - -
Data Sources Disclaimer